Por favor, use este identificador para citar o enlazar este ítem: http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/1382
Título : Análisis del Proceso de Actualización de Medicamentos en el Cuadro Basico y Catálogo de Insumos del Sector Salud
Creador: Rios Pedro Rizo
Nivel de acceso: Open access
Palabras clave : Insumos Farmacéuticos
Análisis Costo-Beneficio
Salud Pública - economía
Salud Pública - estadística & datos numéricos
México
Política de Salud - economía
Metodología
Pharmaceutical Raw Material
Cost-Benefit Analysis
Public Health - economics
Public Health - estadística & datos numéricos
Mexico
Health policy - economics
Methodology
eficacia
eficiencia
evaluación de tecnologías sanitarias
medicamentos
políticas de salud
seguridad
Efficacy
Efficiency
Evaluation of health technologies
Pharmaceutical Preparations
Health policy
security
Descripción : Objectives: The high costs generated by the current epidemiological profile and the introduction of new technologies, impact on public health systems, this situation is complicated when the health budget is low and causes the drug to be paid by the patient's pocket. In this situation it is necessary to design strategies that strengthen the approval of drugs that will be used in public health institutions in Mexico. To describe the results of the drug approval process for use in public health institutions to ensure the efficacy, safety, and efficiency of health technologies used in public health institutions in Mexico. Methods: We conducted a cross-sectional drug approval process, from September 2011 to December 2012, with a descriptive analysis for each stage in the process considered. Results: Of the 394 applications received for approval of health technology, 244 (62%) were for drugs; of these, 151 (62%) met the requirements for evaluation (32% and 68% were modifications inclusions), finally was approved of 42% (61% of the changes and 33% of inclusions). The 73% of the applications were for consensus approval, 12% were conditioned at low price and 6% were approved by majority vote. The main reasons for refusal were lack of clinical evidence (31%) and methodological problems in the economic evaluation (27%). Conclusions: The strengthening of the process was conducted with methodological rigor based on critical analysis of scientific evidence, with transparency and legitimacy under a legal framework to promote resource optimization. The highest percentage of requests was for drugs which are the most commonly used therapeutic technology; for this reason it requires a proper selection process to ensure greater health benefit that ensures efficient use of economic resources. The economic evaluation was a support tool to consider in addition to price, the value of health determined by the quality of evidence, establishing a GDP per capita as a threshold to define a drug as an efficient alternative. © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Colaborador(es) u otros Autores: Rivera A.G.
Oropeza I.R.
Rivas Bocanegra R.E.
Fecha de publicación : 2013
Tipo de publicación: Artículo
Formato: pdf
Identificador del Recurso : 10.1016/j.vhri.2013.09.004
Fuente: Value in Health Regional Issues 2(3):387 - 391
URI : http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/1382
Idioma: spa
Aparece en las colecciones: Artículos

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.